Press Release

<< Back
Mar 02, 2021

Aravive to Participate in Upcoming Virtual Investor Conferences in March

HOUSTON, March 02, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company will present and conduct one-on-one meetings at the following two virtual investor conferences in March:

  • H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021. Aravive’s presentation will be available for viewing on March 9, 2021.
  • Oppenheimer 31st Annual Healthcare Conference on Thursday, March 18, 2021, at 8:00 a.m. ET

Live webcasts and audio archives of the presentations will be available at Archived replays of the webcasts will be available for 90 days following the presentations.

About Aravive
Aravive, Inc. is a clinical-stage oncology company developing transformative therapeutics designed to halt the progression of life-threatening diseases. Aravive is based in Houston, Texas and received a Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016. Aravive’s lead product candidate, AVB-500, is an ultra-high affinity decoy protein that targets the GAS6-AXL signaling pathway associated with tumor cell growth. Aravive successfully completed a Phase 1b trial of AVB-500 in platinum resistant ovarian cancer and plans to initiate a pivotal Phase 3 trial of AVB-500 at a dose of 15 mg/kg. While the Phase 1b trial of AVB-500 in platinum resistant ovarian cancer was a safety trial and not powered to demonstrate efficacy, all 5 patients in the 15 mg/kg cohort experienced clinical benefit, with 1 complete response, 2 partial responses, and 2 stable disease. The Company has initiated and is recruiting for its Phase 1b/2 trial in patients with clear cell renal cell carcinoma.

Sheryl Seapy, W2O
(949) 903-4750

Luke Heagle, W2O
(910) 726-1372